Comparison of Reference and Biosimilar Medications for Pediatric Noninfectious Uveitis
The most common reason for biosimilar initiation was insurance mandate. Compared with the reference infliximab, pediatric patients had fewer number of flares per year on biosimilar infliximab, but they were also on the biosimilar for a shorter duration of time compared with the reference which may confound an accurate assessment. Biosimilar infliximab had a lower cost profile compared with reference infliximab.
Authors
- Jordan D. Deaner (ORCID: https://orcid.org/0000-0002-3899-4456)
- Dilraj Singh Grewal (ORCID: https://orcid.org/0000-0002-2229-5343)
- Nita Valikodath
- Mary Buckley
- Jay Rathinavelu (ORCID: https://orcid.org/0000-0002-7448-164X)
Institutions
- Thomas Jefferson University (US)
- Duke University (US)
- University of Michigan (US)
- Wills Eye Hospital (US)
Publication Details
- Journal
- International Ophthalmology Clinics
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1097/iio.0000000000000530
- Citations
- 3
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 1.62